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Aquaporins (AQPs) belong to a highly conserved group of membrane proteins involved in 
the transport of water and small solutes and with a variety of important physiological roles. The 13 
human AQP isoforms (AQP0-12) are differentially expressed in many types of cells and tissues in the 
body and can be divided into two major groups: those strictly selective for water (called orthodox 
aquaporins), and those that are also permeable to other small solutes including glycerol (called 
“aquaglyceroporins”). The latter include AQP3, AQP7, AQP9 and AQP10 isoforms [1]. Phenotype 
analysis of AQP-null mice, as well as pathophysiological studies, suggested AQPs as drug targets. 
Indeed, it has recently emerged that AQPs are implicated in various diseases such as polycystic 
kidney disease, cataract, brain oedema, gallstone disease and nephrogenic diabetes insipidus, as 
well as in the development of obesity and cancer [2]. Moreover, analysis of AQP involvement in 
the life-cycle of disease causing organisms suggests additional opportunities for pharmacological 
intervention in the treatment of human diseases [3]. 
In recent years, there were reports of chemical compounds that modulate AQP mediated 
water flux including heavy metals [4-7], quaternary ammonium salts [8-10], and inorganic salts 
[11]. Those compounds are valuable for gaining insight into the effect of AQP modulation at a 
cellular level; however, unfortunately, they are not suitable for therapeutic applications mostly 
due to their toxic side effects and lack of selectivity. In addition, recent reports have described 
a few small molecule, organic AQP modulators, mainly sulfonamides, that act as inhibitors of 
orthodox water channels [12], as well as some compounds containing carboxylic groups [13]. Only 
a few small molecule inhibitors of AQP9 glycerol permeability were identified; however, as their 
solubility in aqueous solution is very limited, these compounds are currently not suitable for in vivo 
Abstract
Aquaporins (AQPs) are membrane water/glycerol channels with essential roles in biological 
systems, as well as being promising targets for therapy and imaging. Using a stopped-flow method, 
a series of gold(III), platinum(II) and copper(II) complexes bearing nitrogen donor ligands, such 
as 1,10-phenatroline, 2,2’-bipyridine, 4,4’-dimethyl-2,2’-bipyridine, 4,4’-diamino-2,2’-bipyridine 
and 2,2’;6’,2”-terpyridine, were evaluated in human red blood cells expressing AQP1 and AQP3, 
responsible for water and glycerol movement, respectively. The results showed that the gold(III) 
complexes selectively modulate AQP3 over AQP1. Additionally, another series of gold(III) 
complexex was tested, namely with the dipyridin-2-ylamine (dipyam) ligand, two gold(III) 
complexes with 2-(2’-pyridyl)benzimidazole (PbImH) ligand, and an organometallic gold(III) 
compound with C^N cyclometallated 2-benzylpyridine (pyb-H).
Molecular modeling and density functional theory (DFT) calculations were subsequently 
performed to rationalize the observations and to investigate the possible molecular mechanism 
through which these gold compounds act on their putative target (AQP3). In the absence of any 
crystallographic data, a previously reported homology model was used for this purpose. Combined, 
the findings of this study show that potent and selective modulation of these solute channels is 
possible, however further investigation is required into the selectivity of this class of agents against 
all AQP isoforms and their potential therapeutic uses.
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experiments [14]. 
Within this frame, our group recently reported on the potent and selective inhibition of AQP3 
by a water-soluble gold(III) coordination compound, [Au(phen)Cl2]Cl (phen = 1,10-phenatroline, 
Auphen) (Figure 1). Notably, Auphen resulted to inhibit glycerol transport in human red blood 
cells (hRBC) with an IC50 = 0.80 ± 0.08  μM, while having only a modest inhibitory effect on water 
permeability mediated by AQP1 [15]. Inspired by these initial promising results, we investigated 
other gold-based compounds as possible AQP3 inhibitors in order to achieve basic structure-activity 
relationships, fundamental for drug design. Thus, we selected a series of square planar gold(III) 
complexes containing functionalised bipyridine ligands of general formula [Au(N^N)Cl2][PF6] 
[where N^N = 2,2’-bipyridine, 4,4’-dimethyl-2,2’-bipyridine, and 4,4’-diamino-2,2’-bipyridine, 
Aubipys], as well as the compound [Au(terpy)Cl]Cl2 (terpy = terpyridine, Auterpy) containing 
the tetracoordinated gold(III) chromophore AuN3Cl (Figure 1). Moreover, the 1,10-phenantroline 
derivatives of Pt(II) and Cu(II) were also included in our investigation to compare the effects of 
metal substitution on the AQP3 inhibition potency. Additionally, new series of Au(III) complexes 
with N-donor ligands of different types, as well as an organometallic Au(III) complex with a 
C^N cyclometallated ligand were also screened as possible selective AQP3 inhibitors to improve 
structure-activity relationships studies. 
Figure 1. Structures of the gold(III) complexes reported in the first part of this study.
The effects of the compounds on both water and glycerol permeation were tested by 
stopped-flow spectroscopy on hRBC, which express AQP1 and AQP3 responsible for membrane 
permeability to water and glycerol, respectively [16]. Additionally, density functional theory 
(DFT) and molecular modelling studies allowed to further characterize the mechanisms of AQP3 
inhibition by gold(III) coordination compounds.
1.2. Results and Discussion
1.2.1. Inhibition of hAQP3 by the Aubipy series
Figure 2 shows the effect induced by the metal complexes on AQP1 and AQP3 in hRBC 
in comparison to HgCl2, the benchmark inhibitor of aquaporin activity [17]. The compounds 
were tested at different concentrations by incubating the samples for 30 min at room temperature 
(RT) until maximum of inhibition was reached (see Experimental Section for details) [15]. All 
the gold(III) compounds showed no or a modest effect on water permeability, while being able 
to drastically reduce glycerol transport. The obtained results demonstrate that all the gold(III) 
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complexes are the most effective inhibitors of glycerol permeability via AQP3, with IC50 in the low 
micromolar range (Table 1), and comparable in potency to Auphen. Within the metal-compounds 
series, the AQP3 inhibition potency decreased drastically in the order Auphen > Cuphen >> Ptphen 
(Figure 2, Table 1). 
Compound IC50[a] Hill Slope
Aubipy 2.3 ± 0.7 1.86 ± 0.4
AubipyMe 1.0 ± 0.4 1.76 ± 0.6
AubipyNH2 2.9 ± 1.1 3.08 ± 0.8
Auterpy 1.0 ± 0.2 2.15 ± 0.3
Auphen 0.8 ± 0.1 [b] 3.9 ± 0.3
Cuphen 81.9 ± 4.1 2.0 ± 0.5
Ptphen > 200 -
Table 1. IC50 (μM) values of metal complexes.
[a] Mean ± SE of at least three determinations. [b] from ref [15].
Figure 2. A: Inhibition of the osmotic water (AQP1) or glycerol (AQP3) permeability (P) in human RBC induced by different 
metal complexes after 30 min incubation at RT.; B: Concentration dependent inhibition of glycerol permeability (P) in hRBC 
by representative metal compounds; C: Inhibition of glycerol permeability (P, % of control) of hRBCs after Aubipy and Auterpy 
treatment (30 min at RT, 2 mM and 5 mM, respectively), and reversibility by incubation with 2-mercaptoethanol (1 mM for 30 
min) (***p < 0.001). D: Arrhenius plot of hRBC glycerol permeability in the absence (control) or presence of 5 mM Auterpy (30 
min incubation at RT previous to permeability measurements). Activation energy (Ea) values for glycerol permeation increased 
drastically when Auterpy was present (7.0 ± 0.06 to 15.2 ± 1.3 kcal mol-1).
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Moreover, all the Hill slope values are greater than 1 (Table 1), suggesting a possible 
cooperative binding effect. Actually, knowing that the aquaporin channels are tetrameric proteins 
in the membrane and each tetramer is formed by four identical monomers, the total of four Cys40 
residues are available for binding. Thus, the Hill slope (H) value for Auphen (ca. 4. Table 1) points 
to a maximal cooperativity and correlates well with its high potency while for the other gold 
compounds, with the exception of AubipyNH2 that showed a slightly higher H value, all the H 
values were close to 2 suggesting an intermediate cooperativity.
The activation energy (Ea) for water and glycerol transport, a valuable parameter indicating 
the contribution of protein channels to permeation, was also estimated from an Arrhenius plot. 
Representative results for Auterpy are shown in Figure 2D. The observed increase in Ea, similarly 
to what we previously observed for Auphen [15], is in accordance with a blockage of the AQP3 
channel.
In order to obtain information on the possible binding sites of the gold complexes in AQP3, 
hRBCs pre-treated with compounds for 30 min at RT were subsequently washed with the reducing 
agent 2-mercaptoethanol (EtSH, 1 mM) according to established procedures [17]. As observed 
for Auphen [15], incubation of the treated hRBC sample with excess EtSH produced an almost 
complete recovery of glycerol permeability (ca. 90%), suggesting that EtSH effect on cysteine 
residues is competing with gold binding to the pore. Representative results for Auterpy and Aubipy 
are shown in Figure 2C. These results, as well as the known affinity of gold ions for binding to 
sulfhydryl groups of proteins, suggest that AQP3 inhibition by Au complexes may involve direct 
protein binding of the Au centre to Cys residues, as it has already been described for HgCl2 [18]. 
1.2.2. Expanding the series of gold(III) compounds
Following the above mentioned promising results on Auphen and Aubipy derivatives and the 
knowledge that the gold centre plays a crucial role in AQP inhibition, it is important to deepen our 
understanding on the structure-activity relationships of gold-based complexes as AQPs inhibitors. 
For this purpose, four new gold(III) compounds (Figure 3) were tested on hRBC using stopped-
flow spectroscopy. The new series included: a gold(III) complex with the dipyridin-2-ylamine 
(dipyam) ligand [Au(dipyam)Cl2][PF6] (AuDipyAm) [19], closely related to the above mentioned 
bipyridine series, two gold(III) complexes with 2-(2’-pyridyl)benzimidazole (PbImH) ligand, 
and an organometallic gold(III) compound with C^N cyclometallated 2-benzylpyridine (pyb-H) 
((pyb-H)AuCl2) [20]. 
 As previously observed for Auphen and Aubipys, the a few of the new compounds act as 
inhibitors of glycerol transport via AQP3, but not of water transport via AQP1. The obtained results 
are summarized in Figure 3. One of the least active complexes of the series is the organometallic 
compound (pyb-H)AuCl2, that did not show inhibition up to 50 μM. It should be noted that the 
organometallic bond renders the gold centre less reactive and the compound generally more stable, 
with respect to ligand exchange reactions, than a classical metal-ligand coordination bond. Thus, the 
observed scarce inhibition may be due to such reduced reactivity of this compound. Interestingly, 
the coordination compound Audipyam, although with a similar scaffold as the organometallic 
complex, shows low inhibition of glycerol permeation, but still with an IC50 value above 20 μM 
which is not ideal for a selective inhibitor. It is worth mentioning that, in addition to differences in 
ligand exchange reactivity, the two compounds may differ also in other chemicophysical properties, 
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such as for example the electrophilicity of the gold centre and the redox potential, which may 
account for the observed differences in AQP3 inhibition.
Figure 3. Structures of the gold(III) compounds studied as hAQP3 inhibitors in hRBC model, relative IC50 (μM) inhibition 
values  and Hill slope (Mean ± SE of at least three determinations).
The other two tested coordination compounds are both gold(III) drugs based on N-donor 
pyridyl-benzimidazole ligand. The first, AuPbImH has been previously published as the lead 
compound in a series of Au(I) and Au(III) mono and binuclear derivatives with anticancer properties 
in vitro [20]. Interestingly, this compound showed to be active in two human ovarian carcinoma 
cell lines, A2780 and A2780cisR, with IC50 of 6.60 ± 4.01 μM and 5.31 ± 0.66 μM, respectively. The 
second cell line is resistant to cisplatin and the ratio between the two, close to 1, reveals that this 
drug does not appear to follow the same toxic route as cisplatin and is effective on both cell lines 
in a similar manner. As promising as this compound may appear as antiproliferative agent, in our 
hRBC model it was not one of the most active compounds inhibiting glycerol transport, with an 
IC50 greater than 50 μM (more than 10-fold difference with respect to the Aubipy series). 
Notably, the AuPbImMe complex, containing the 1-methyl-2-(2’-pyridyl)benzoimidazole 
ligand, is the most potent of the four new tested compounds, with an IC50 of 0.57 ± 0.13 μM, 
even more effective than Auphen, and ca. two orders of magnitude more potent than the related 
AuPbImH complex. As shown in Figure 3, the only difference with AuPbImH is the addition of a 
CH3 group to one of the nitrogen atoms in the benzoimidazole ring, conferring a positive charge 
to the resulting complex. In spite of the fact that this seems to be a small structural difference, 
this addition may influence the reactivity of the gold(III) centre as well as its chemicophysical 
properties (e.g. redox potential), and further studies are necessary to fully rationalize how such 
differences may affect the AQP3 inhibition of the two complexes so radically. 
In order to study the reversibility of inhibition, hRBCs were pre-treated with the drugs 
for 30 min at RT and subsequently washed with the reducing agent 2-mercaptoethanol (EtSH, 1 
mM), according to established procedures [17]. In Figure 4B it is clear the inhibition of glycerol 
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permeation by 1 μM AuPbImMe is not affected after washing cells with PBS buffer. Conversely, 
as observed for the previously studied gold compounds, washing with excess EtSH (Phosphate 
β-Mercaptoethanol, BME buffer) led to an almost complete recovery of glycerol permeability. Since 
EtSH is a very strong reducing agent, one cannot exclude that the inhibition by gold(III) compounds 
may be due to oxidation of the thiol group of Cys residues, which may be then reversed by EtSH 
addition. Therefore, in order to exclude possible oxidative effects by Au(III), we investigated the 
reversibility of inhibition by AuPbImMe by washing the hRBC with 1 mM of L-cysteine, which 
while maintaining its affinity to gold binding, is not a reducing agent. Interestingly, recovery after 
washing with L-Cys seems to similar to EtSH washing, suggesting that there is no oxidation of Cys, 
but that L-Cys may simply compete with Cys residues for binding to gold. 
A B
Figure 4. A: Time-dependence glycerol inhibition (% of control) for two concentrations of AuPbImMe; B: Inhibition of glycerol 
permeability (% of control) of hRBCs after AuPbImMe treatment (30 min at RT, 1 μM), and reversibility by incubation with 
2-mercaptoethanol (BME) and L-Cys (1 mM for 30 min). The results shown represent the average of, at least, three independent 
experiments ± SE.
1.2.3. Mechanism of Aquaporins Inhibition by Gold(III) compounds
Our group has previously reported a model for the selective inhibition of AQP3 by Au(III) 
channel blockers, including Auphen [15]. The resulting mechanistic hypothesis suggests that the 
metal coordinates to a specific nucleophilic site, namely the side chain of Cys40, which is located 
at the extracellular side of AQP3 in close proximity to the selectivity filter (SF) region, therefore, 
inducing the blockage of the channel upon binding  (Figure S2 in Supplementary Material). In 
AQP1, Cys189 is also located in the protein extracellular domain and is part of the SF region, but 
it is deeply buried in the channel and its thiol group is poorly available for binding to the bulky 
Au(III) complexes [15]. In fact, previously reported non-covalent docking studies of Auphen in 
AQP1 have shown that the side chain of Cys189 is distant from the gold ion (12-14 Å) and not 
favourably oriented for the binding to occur. In this context, the selective inhibition of AQP3 vs 
AQP1 is mainly related to the lack of possible gold binding sites in the extracellular pocket of AQP1 
accessible to such relatively bulky metal complexes [15]. 
According to the proposed inhibition mechanism, the electrophilicity of the metal centre is 
expected to play a role in determining the reactivity of the complexes towards AQP3. Therefore, we 
carried out DFT calculations to characterize the electrophilicity of the considered Au(III), Pt(II) 
and Cu(II) complexes using the perturbative approach in terms of atomic charges and frontier 
orbitals proposed by Klopman [21]. Natural atomic orbital population analyses (Table 2) highlight 
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similar charges on the metal centre for all monocationic Au(III) complexes. A higher charge is 
observed on the gold(III) center of Auterpy, as expected, for dicationic species, while the metal 
of neutral Cuphen and Ptphen complexes is almost the same or less positively charged than the 
gold(III) center of monocationic complexes, respectively (Table 2). Thus, charge factors indicate 
the following order of reactivity towards nucleophiles: Auterpy > (Auphen, Aubipy analogues) > 
(Cuphen, Ptphen).
Compound Mn+ Cl N
AubipyCl2 1.09 -0.35 -0.49
AubipyMeCl2 1.10 -0.36 -0.50
AubipyNH2Cl2 1.10 -0.37 -0.53
Auterpy 1.22 -0.38 -0.48, -0.49[a]
Auphen 1.09 -0.35 -0.49
Cuphen 0.66 -0.44 -0.50
Ptphen 1.10 -0.65 -0.52
Table 2. Mulliken and natural atomic orbital (NAO) charges.
[a] The two values reported for Auterpy N refer to the two reciprocal trans and the one Cl-trans pyridyl nitrogens, respectively.
On the other hand, the analysis of frontier orbitals (see Figure S3 in Supplementary Material) 
shows similar LUMO energies for all monocationic Au(III) complexes. Auterpy shows a significant 
lower LUMO energy, whereas Cuphen and Ptphen are characterized by the highest LUMO. Thus, 
frontier orbital factors suggest an order of reactivity towards nucleophiles substantially inverse to 
that indicated by charge factors: (Cuphen, Ptphen) > (Auphen, Aubipy analogues) > Auterpy. The 
charge and orbital factors probably compensate for each other in the Au(III) compounds, thus 
leading to similar reactivity towards cysteine, while the charge factors seems to prevail for the 
Cu(II) and Pt(II) complexes which are much less reactive, in agreement with the observed AQP3 
inhibition potency, see Table 1. 
 The thermodynamics of the ligand 
exchange process leading to covalently 
bound Au(III)-AQP3 adducts was then 
investigated at DFT level of theory, which 
has been recently shown to give good results 
for the reactivity of Au(III) compounds 
[22]. In particular, the exchange of the Cl- 
anion, by using CH3SH as a model of the 
Cys40 side-chain, was analyzed (See Figure 
5). As previously reported, in physiological 
conditions (pH 7.4) the cysteine residue 
(pKa = 8.3) is prevalently, but not 
exclusively, protonated and this process can 
be considered as result of: either the initial 
nucleophilic attack of the neutral cysteine 
Figure 5. Reaction scheme of the considered Au(III) complexes 
with the Cys40 side-chain model leading to the final Au(III)-thiolate 
complexes.
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with formation of an Au(III)-thiol complex followed by its easy deprotonation, or the initial 
cysteine deprotonation followed by the attack of the more nucleophilic thiolate anion giving the 
final Au(III)-thiolate complex. In any case, the whole reaction is thermodynamically favoured for 
all the gold(III) complexes, with binding energies to Cys40 similar to those previously calculated 
for Auphen [15] (See Table 3) accounting for the good AQP3 inhibition potency observed for all 







Table 3. Calculated free energies for the reaction of the investigated Au(III) 
complexes with  the cysteine side-chain model. All values are in kJ mol-1.
We also investigated the initial approach of the various metal complexes to the Cys40 residue 
in the channel pore from the extracellular side and the possible formation of non-covalent adducts 
with Cys40 itself or other neighbouring residues within the active site. To this purpose, quantum 
mechanics/molecular mechanics (QM/MM) calculations at DFT level of theory were performed 
by using the previously proposed AQP3 homology model [15], and by optimizing several possible 
initial poses of the complexes in the extracellular pocket around the Cys40 residue. In Figure 6A, 
the calculated most stable binding mode of AubipyMe at the AQP3 extracellular binding pocket 
is reported. The complex lies perpendicular to the membrane plane and the Au-S(Cys40) distance 
is around 5.8 Å. As detailed in the interaction diagram depicted in Figure 6B, the compound 
establishes π-π stacking interactions with Tyr212 and Phe63, two of the residues representing 
the arginine-aromatic (ar/R) constriction (the selectivity filter, SF) typical of AQPs [23]. Along 
with π-π interactions, the gold(III) complex also interacts via further hydrophobic contacts of the 
bipy methyl substituents with Ile59, Val67 and Val199. The results also show the proximity of the 
complex to the Arg218 side-chain, whose positive charge might play a role in stabilizing the leaving 
chloride in the binding of the metal centre to Cys40. Thus, calculations showed how the placement 
of the metal complexes in the AQP3 extracellular pocket is controlled by both covalent anchoring 
to Cys40 and by non-covalent interactions; the latter may be crucial in the channel blockage by 
favouring the bury of the constriction region of the channel.
1.3. Conclusions
Numerous reports have highlighted the possible areas where AQP modulators could be 
useful in treating human diseases. Yet, only a few pharmaceutically relevant compounds have been 
identified to date. We described here the selective and potent inhibitory effect of a series of Au(III) 
complexes bearing nitrogen donor ligands on AQP3, which together with their high water solubility 
makes them suitable candidates for future in vivo studies. AQP3 has been shown to mediate most 
of the glycerol movements across RBCs membranes. In addition to its expression in hRBCs, 
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AQP3 has a wide tissue distribution in the epithelial cells of kidney, airways and skin, suggesting 
a role in water reabsorption, mucosal secretions, skin hydration and cell volume regulation [24]. 
Moreover, recent studies demonstrated an aberrant AQP3 expression in tumor cells of different 
origins, particularly aggressive tumors [24-27] suggesting this enhanced protein expression to be 
of diagnostic and prognostic value. 
Interestingly, the gold(III) complexes herewith described possess cytotoxic anticancer 
properties in vitro, and in recent years several gold compounds have shown promising anticancer 
effects related to the inhibition of different protein targets, such as the thioredoxin reductases, 
the proteasome and certain zinc-finger proteins [28-30]. In this context, we cannot exclude that 
inhibition of AQP3 might also contribute to the biological effects of the gold(III) compounds 
towards cancer cells, although other studies are on-going in our labs to validate such a hypothesis. 
Moreover, the inhibition properties of the compounds towards the other aquaglyceroporin isoforms 
involved in essential physiological pathways should be further investigated in order to optimize the 
drug design and to achieve highly selective molecules with reduced risks of side effects.
Finally, it is worth mentioning that, although the only organometallic Au(III) complex did not 
show AQP3 inhibitor ((pyb-H)AuCl2), other families of gold compounds containing a direct metal-
carbon bond should be tested before discarding them as suitable AQPs modulators. As a matter of 
fact, organometallic compounds have the advantage over classical coordination complexes (e.g. 
with only N-donor ligands bound to the metal centre) to be more stable and with a reactivity that 
can be fine-tuned by appropriate modifications of the ligand scaffold, i.e. an essential requisite to 
design biologically active compounds.
1.4. Experimental Section
Chemistry: Gold compounds were prepared according to literature procedures [19, 20, 31]. The purity of the 
compounds was confirmed by elemental analysis, and all of them showed purity greater than 98%. Copper and 
platinum 1,10-phenantroline and 2-mercaptoethanol were from Sigma.
Ethics Statement: Venous blood samples were obtained from healthy human volunteers following a protocol approved 
by the Ethics Committee of the Faculty of Pharmacy of the University of Lisbon. Informed written consent was obtained 
from all participants. 
Figure 6. A: Hypothetical binding mode of AubipyMe inside the AQP3 periplasmic pocket. The Au(III)-complex and Cys40 
side chain are shown in ball and sticks. Side-chains of SF domain residues are reported as grey sticks. Residues interacting 
through hydrophobic contacts with the ligand are displayed as surfaces. B: Interaction diagram of AubipyMe inside the AQP3 
extracellular pocket.
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Erythrocyte sampling and preparation: Venous blood samples were collected in citrate anticoagulant (2.7 % citric 
acid, 4.5 % trisodium citrate and 2% glucose). Fresh blood was centrifuged at 750 xg for 5 min at 4 ºC and plasma and 
buffy coat were discarded. Packed erythrocytes were washed three times in PBS (KCl 2.7 mM, KH2PO4 1.76 mM, 
Na2HPO4 10.1 mM, NaCl 137 mM, pH 7.4), diluted to 0.5% haematocrit and immediately used for experiments. hRBC 
mean volume in isotonic solution was determined using a CASY-1 Cell Counter (Schärfe System GmbH, Reutlingen, 
Germany) and was calculated as 82 fL.
Stopped-flow light scattering experiments: Stopped-flow experiments were performed on a HI-TECH Scientific PQ/
SF-53 apparatus, with 2 ms dead time, temperature controlled and interfaced with a microcomputer. Experiments were 
performed at 23 ºC for glycerol permeability and at 10 ºC for water permeability; for activation energy measurements 
temperatures were ranged from 10 ºC to 37 ºC. For each experimental condition, 5-7 replicates were analysed. For 
measuring the osmotic water permeability (Pf), 100 mL of a suspension of fresh erythrocytes (0.5%) was mixed with an 
equal volume of PBS containing 200 mM sucrose as a non-permeable osmolyte to produce a 100 mM inwardly directed 
sucrose gradient. The kinetics of cell shrinkage was measured from the time course of 90º scattered light intensity at 
400 nm until a stable light scatter signal was attained. 
Pf was estimated by Pf = k (Vo/A)(1/Vw(osmout)∞), where Vw is the molar volume of water, Vo/A is the initial cell 
volume to area ratio and (osmout)∞ is the final medium osmolarity after the applied osmotic gradient and k is the single 
exponential time constant fitted to the light scattering signal of erythrocyte shrinkage. 
For glycerol permeability (Pgly), 100 mL of erythrocyte was mixed with an equal volume of hyperosmotic PBS 
containing 200 mM glycerol creating a 100 mM inwardly directed glycerol gradient. After the first fast cell shrinkage 
due to water outflow, glycerol influx in response to its chemical gradient was followed by water influx with subsequent 
cell reswelling. Pgly was calculated as Pgly = k (Vo/A), where k is the single exponential time constant fitted to the 
light scattering signal of glycerol influx in erythrocytes. For inhibition experiments cells were incubated with different 
concentrations of complexes, from freshly prepared stock aqueous solutions, for various times at room temperature 
before stopped-flow experiments. A time dependent inhibition assay for all the tested compounds over several hours 
incubation with hRBC showed no further increase of inhibition after 30 min at r.t. Inhibitors’ reversibility was tested 
by 30 min incubation of hRBCs with the compounds followed by further incubation with 1 mM 2-mercaptoethanol 
(EtSH) for 30 min at room temperature. The reversibility assays were also performed under the same conditions, using 
1 mM L-cysteine. The inhibitor concentration necessary to achieve 50% inhibition (IC50) was calculated by nonlinear 
regression of dose-response curves (Graph Pad Prism, Inc) to the equation: y=ymin+(ymax-ymin)/(1+10((LogIC50-
Log[Inh]) H)), where y is the percentage inhibition obtained for each concentration of inhibitor [Inh] and H is the Hill 
slope. The activation energy (Ea) of water and glycerol transport was calculated from the slope of the Arrhenius plot 
(lnPf or lnPgly as a function of 1/T) multiplied by the gas constant R. All solution osmolarities were determined from 
freezing point depression on a semi-micro osmometer (Knauer GmbH, Berlin, Germany) using standards of 100 and 
400 mOsM.
Statistic analysis: Data were presented as mean ± standard error of the mean (SEM) of at least four independent 
experiments, and were analysed with either the paired Student’s t-test or one-way analysis of variance (ANOVA) 
followed by Tukey’s test. A value of P = 0.01 was considered to be statistically significant. 
QM calculations: The structures of Au(III), Cu(II) and Pt(II) complexes were investigated at DFT level of theory with 
the B3LYP hybrid functional [32, 33]. The core electrons of the chloride and metal atoms were described with the Hay 
and Wadt core-valence relativistic effective core-potential (ECP) leaving the outer electrons to be treated explicitly 
through the basis set denoted as LACVP** in Jaguar, while for the remaining atoms the 6-31G** basis set was used [34]. 
Each structure was optimized in the gas phase (a=0) and frequency calculations were performed to verify the correct 
nature of the stationary points and to estimate zero point energy (ZPE) and vibrational entropy corrections at room 
temperature. Single point energies of all stationary points were calculated by using the larger 6-311++G** set for the 
main group elements, and the LACV3P++** set for the metal and the chloride atoms.  At this level of theory, Mulliken 
[34] and natural atomic orbital[40] population analyses were also performed. The Poisson-Boltzmann (PB) continuum 
solvent method was employed to simulate the aqueous medium (ε = 80) [35]. The values of DGII for methanethiol 
species have been calculated by using a thermodynamic cycle as previously reported [15]. The Jaguar 7.9 quantum 
chemistry package (Jaguar, version 7.9, Schrödinger, LLC, New York, NY, 2012) was used for all calculations.
QM/MM calculations: Hybrid quantum mechanics molecular mechanics (QM/MM) calculations have been 
performed with the Qsite 5.8 software package (QSite, version 5.8, Schrödinger, LLC, New York, NY, 2012). As, to date, 
no crystallographic information about the AQP3 is available, we performed the studies by using a AQP3 homology 
model [15], which has been previously reported and built by using the crystal structure of the Escherichia coli glycerol 
facilitator (GlpF) [36] as template (PDB ID code: 1LDF). 
The starting complexes have been set up manually by placing the Au(III) centre in the proximity of the Cys40 side-
chain, which is expected to react with the metal centre. To sped up the calculations, the QM region as been limited to 
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the Au(III) complex and has been treated at DFT level of theory with the B3LYP functional [M1, M2] and the LACVP** 
basis set [37], whereas the MM system, consisting of protein atoms, has been described with the OPLSA_2001 force 
field [38, 39]. Protein atoms have been kept frozen at their initial coordinates and only the side-chain atoms of Cys40, 
Phe63, Tyr212 and Arg218 have been allowed to relax during the optimization. 
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